|
1
|
Krychman ML and Katz A: Breast cancer and
sexuality: multi-modal treatment options. J Sex Med. 9:5–13. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haas JS, Liang SY, Hassett MJ, Shiboski S,
Elkin EB and Phillips KA: Gene expression profile testing for
breast cancer and the use of chemotherapy, serious adverse effects,
and costs of care. Breast Cancer Res Treat. 130:619–626. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi JW, Lee JS, Kim SW and Yun CO:
Evolution of oncolytic adenovirus for cancer treatment. Adv Drug
Deliv Rev. 64:720–729. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang JH, Zhang SN, Choi KJ, et al:
Therapeutic and tumor-specific immunity induced by combination of
dendritic cells and oncolytic adenovirus expressing IL-12 and
4-1BBL. Mol Ther. 18:264–274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hashimoto Y, Tazawa H, Teraishi F, et al:
The hTERT promoter enhances the antitumor activity of an oncolytic
adenovirus under a hypoxic microenvironment. PLoS One.
7:e392922012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fang L, Pu YY, Hu XC, et al:
Antiangiogenesis gene armed tumor-targeting adenovirus yields
multiple antitumor activities in human HCC xenografts in nude mice.
Hepatol Res. 40:216–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cho WK, Seong YR, Lee YH, et al: Oncolytic
effects of adenovirus mutant capable of replicating in hypoxic and
normoxic regions of solid tumor. Mol Ther. 10:938–949. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ulasov IV, Zhu ZB, Tyler MA, et al:
Survivin-driven and fiber-modified oncolytic adenovirus exhibits
potent antitumor activity in established intracranial glioma. Hum
Gene Ther. 18:589–602. 2007. View Article : Google Scholar
|
|
9
|
Kim KI, Park JH, Lee YJ, et al: In vivo
bioluminescent imaging of α-fetoprotein producing hepatocellular
carcinoma in diethylnitrosamine-treated mouse using recombinant
adenoviral vector. J Gene Med. 14:513–520. 2012.
|
|
10
|
Kwon OJ, Kim PH, Huyn S, Wu L, Kim M and
Yun CO: A hypoxia- and α-fetoprotein-dependent oncolytic adenovirus
exhibits specific killing of hepatocellular carcinomas. Clin Cancer
Res. 16:6071–6082. 2010.
|
|
11
|
Nakagawa T, Tanaka H, Shirakawa T, et al:
Cyclooxygenase 2 promoter-based replication-selective adenoviral
vector for hypopharyngeal cancer. Arch Otolaryngol Head Neck Surg.
135:282–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bauerschmitz GJ, Guse K, Kanerva A, et al:
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter,
E1A transcomplementation, and serotype chimerism for enhanced
selectivity for ovarian cancer cells. Mol Ther. 14:164–174. 2006.
View Article : Google Scholar
|
|
13
|
Ganesh S, Gonzalez-Edick M, Gibbons D,
Waugh J, Van Roey M and Jooss K: Evaluation of biodistribution of a
fiber-chimeric, conditionally replication-competent (oncolytic)
adenovirus in CD46 receptor transgenic mice. Hum Gene Ther.
20:1201–1213. 2009. View Article : Google Scholar
|
|
14
|
Hoffmann D, Meyer B and Wildner O:
Improved glioblastoma treatment with Ad5/35 fiber chimeric
conditionally replicating adenoviruses. J Gene Med. 9:764–778.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wakayama M, Abei M, Kawashima R, et al:
E1A, E1B double-restricted adenovirus with RGD-fiber modification
exhibits enhanced oncolysis for CA-deficient biliary cancers. Clin
Cancer Res. 13:3043–3050. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ries SJ, Brandts CH, Chung AS, et al: Loss
of p14ARF in tumor cells facilitates replication of the adenovirus
mutant dl1520 (ONYX-015). Nat Med. 6:1128–1133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Harada JN and Berk AJ: p53-Independent and
-dependent requirements for E1B-55K in adenovirus type 5
replication. J Virol. 73:5333–5344. 1999.PubMed/NCBI
|
|
18
|
Heise C, Hermiston T, Johnson L, et al: An
adenovirus E1A mutant that demonstrates potent and selective
systemic anti-tumoral efficacy. Nat Med. 6:1134–1139. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang ZL, Zou WG, Luo CX, et al: An armed
oncolytic adenovirus system, ZD55-gene, demonstrating potent
antitumoral efficacy. Cell Res. 13:481–489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian H, Wang J, Zhang B, et al:
MDA-7/IL-24 induces Bcl-2 denitrosylation and ubiquitin-degradation
involved in cancer cell apoptosis. PLoS One. 7:e372002012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jiang G, Liu YQ, Wei ZP, Pei DS, Mao LJ
and Zheng JN: Enhanced anti-tumor activity by the combination of a
conditionally replicating adenovirus mediated interleukin-24 and
dacarbazine against melanoma cells via induction of apoptosis.
Cancer Lett. 294:220–228. 2010. View Article : Google Scholar
|
|
22
|
Halldén G: Optimisation of
replication-selective oncolytic adenoviral mutants in combination
with chemotherapeutics. J BUON. 14(Suppl 1): S61–S67.
2009.PubMed/NCBI
|
|
23
|
Saito K, Shirasawa H, Isegawa N, Shiiba M,
Uzawa K and Tanzawa H: Oncolytic virotherapy for oral squamous cell
carcinoma using replication-competent viruses. Oral Oncol.
45:1021–1027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khuri FR, Nemunaitis J, Ganly I, et al: A
controlled trial of intratumoral ONYX-015, a
selectively-replicating adenovirus, in combination with cisplatin
and 5-fluorouracil in patients with recurrent head and neck cancer.
Nat Med. 6:879–885. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cherubini G, Kallin C, Mozetic A, et al:
The oncolytic adenovirus AdΔΔ enhances selective cancer cell
killing in combination with DNA-damaging drugs in pancreatic cancer
models. Gene Ther. 18:1157–1165. 2011.
|
|
26
|
Bhattacharyya M, Francis J, Eddouadi A,
Lemoine NR and Halldén G: An oncolytic adenovirus defective in
pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer
cells and tumors in vivo in combination with 5-FU or gemcitabine.
Cancer Gene Ther. 18:734–743. 2011. View Article : Google Scholar
|
|
27
|
Ingemarsdotter CK, Baird SK, Connell CM,
Öberg D, Halldén G and McNeish IA: Low-dose paclitaxel synergizes
with oncolytic adenoviruses via mitotic slippage and apoptosis in
ovarian cancer. Oncogene. 29:6051–6063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao Y, Nankya I, Abraha A, et al:
Calculating HIV-1 infectious titre using a virtual TCID(50) method.
Methods Mol Biol. 485:27–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Walker RA, Hanby A, Pinder SE, Thomas J
and Ellis IO; National Coordinating Committee for Breast Pathology
Research Subgroup. Current issues in diagnostic breast pathology. J
Clin Pathol. 65:771–785. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wong HH, Lemoine NR and Wang Y: Oncolytic
viruses for cancer therapy: overcoming the obstacles. Viruses.
2:78–106. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cun B, Song X, Jia R, et al: Combination
of oncolytic adenovirus and dacarbazine attenuates antitumor
ability against uveal melanoma cells via cell cycle block. Cancer
Biol Ther. 13:77–84. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Abate-Daga D, Andreu N, Camacho-Sánchez J,
et al: Oncolytic adenoviruses armed with thymidine kinase can be
traced by PET imaging and show potent antitumoural effects by
ganciclovir dosing. PLoS One. 6:e261422011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu RL, Post DE, Khuri FR and Van Meir EG:
Use of replicating oncolytic adenoviruses in combination therapy
for cancer. Clin Cancer Res. 10:5299–5312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Menzin AW, King SA, Aikins JK, Mikuta JJ
and Rubin SC: Taxol (paclitaxel) was approved by FDA for the
treatment of patients with recurrent ovarian cancer. Gynecol Oncol.
54:1031994.PubMed/NCBI
|
|
35
|
Flores ML, Castilla C, Ávila R,
Ruiz-Borrego M, Sáez C and Japón MA: Paclitaxel sensitivity of
breast cancer cells requires efficient mitotic arrest and
disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat.
133:917–928. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu PH, Yu CC, Chiang PC, et al: Paclitaxel
induces apoptosis through activation of nuclear protein kinase C-δ
and subsequent activation of Golgi associated Cdk1 in human hormone
refractory prostate cancer. J Urol. 186:2434–2441. 2011.
|
|
37
|
Le XF, Mao W, He G, et al: The role of
p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human
ovarian cancer cells. J Natl Cancer Inst. 103:1403–1422. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heikaus S, Matuszek KS, Suschek CV, et al:
Paclitaxel (Taxol)-induced apoptosis in human epithelioid sarcoma
cell lines is enhanced by upregulation of CD95 ligand
(FasL/Apo-1L). J Cancer Res Clin Oncol. 134:689–695. 2008.
View Article : Google Scholar : PubMed/NCBI
|
